Ocuphire

View the org chart displaying its 21 main executives

Most searched biographies at Ocuphire

• George Magrath, Chief Executive Officer and Director
• Sean Ainsworth, Director
• Jay Pepose, Director

Popular executive movements at Ocuphire

• Nirav Jhaveri has joined the company as Chief Financial Officer  (posted on February 15 2024).
• Ash Jayagopal has joined the company as Chief Scientific and Development Officer  (posted on February 15 2024).
• Ronil Patel, who was Senior Vice President of Operations and Business Development, is promoted to Chief Business Officer  (posted on December 7 2023).

Click here to view some more movements at Ocuphire

Create your alert
to follow the executive moves at Ocuphire.

Ocuphire has 1,861 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• MedMen has filed for bankruptcy protection  (posted on April 28 2024).
• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director at Dirk Rossmann
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma

Learn more about the Pharmaceuticals industry >

Press releases by Ocuphire

• First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
• Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
• Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
• Ocuphire Pharma to Present in the BIO CEO & Investor Conference
• Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Ocuphire Pharma Strengthens Leadership Team with Key Appointments
• Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
• Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
• Press Releases
• View more press releases Close

Social media about Ocuphire

• Ocuphire on Wikipedia, Google News & Yahoo Finance
• Ocuphire on LinkedIn, Twitter & YouTube

Contact by email its executives including George Magrath

Call Ocuphire at +1 24...

View the org chart

Register to receive your alert

Report an error